Healthcare Jun 28, 2022 09:50 AM (GMT+8)
On June 25, GSK announced that the interim results of phase IIB clinical treatment of chronic hepatitis B with bepirovirsen (gsk3228836, gsk836) were positive. The data showed that after 24 weeks of bepirovirsen treatment, the levels of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA decreased in patients with chronic hepatitis B, which is expected to achieve functional cure.
In addition to monotherapy, GSK also explored the efficacy of bepirovirsen combined therapy in the treatment of chronic hepatitis B in the following trials, including the phase IIB clinical trial of bepirovirsen combined with pegifn; Phase II clinical trial of bepirovirsen combined with GSK targeted immunotherapy for chronic hepatitis B.
This text is a result of machine translation.